A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis

Pharmacogenomics Journal

Volumn 16, Issue 2, 2016, Pages 147-150

  Juli, A ^a   Fernandez Nebro, A ^b   Blanco, F ^c   Ortiz, A ^d   Canete J D ^e   Maymo J ^f   Alperi Lopez M ^g   Fernandez Gutierrez B ^h   Oliv, A ⁱ   Corominas, H ^j   Erra, A ^k   Acosta Colman, I ^a   Alonso, A ^a   Lopez Lasanta M ^a   Tortosa, R ^a   Tornero, J ^l   Marsal, S ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c UNIVERSITY OF A CORUÑA   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^j D'Oriol Martorell   (Spain)

^k Hospital Sant Rafael   (Spain)

^l HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; GENETIC MARKER; MAFB PROTEIN, HUMAN; MED15 PROTEIN, HUMAN; MEDIATOR COMPLEX; TRANSCRIPTION FACTOR MAFB; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; MAFB GENE; MAJOR CLINICAL STUDY; MALE; MED15 GENE; PHARMACOGENETICS; PRIORITY JOURNAL; REPLICATION STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM;

ADALIMUMAB; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ETANERCEPT; FEMALE; GENETIC LOCI; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INFLIXIMAB; MAFB TRANSCRIPTION FACTOR; MALE; MEDIATOR COMPLEX; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928138633     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.31     Document Type: Article

References (37)

1. Taylor PC, Feldmann M. AntiTNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 578-582
2. Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011; 63: 939-948
3. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to antiTumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-1523
4. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with antiTumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 69-74
5. Plant D, Wilson AG, Barton A. Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol 2014; 10: 329-337
6. Julia A, Erra A, Palacio C, Tomas C, Sans X, Barcelo P et al. An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS One 2009; 4: e7556
7. Kapoor SR, Filer A, Fitzpatrick MA, Fisher BA, Taylor PC, Buckley CD et al. Metabolic profiling predicts response to antiTumor necrosis factor alpha therapy in patients with rheumatoid arthritis. Arthritis Rheum 2013; 65: 1448-1456
8. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014; 506: 376-381
9. Julia A, Marsal S. The genetic architecture of rheumatoid arthritis: from susceptibility to clinical subphenotype associations. Curr Top Med Chem 2013; 13: 720-731
10. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to antiTNF treatment in rheumatoid arthritis. Mol Med 2008; 14: 575-581
11. Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG et al. Genome-wide association study of genetic predictors of antiTumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 2011; 63: 645-653
12. Krintel SB, Palermo G, Johansen JS, Germer S, Essioux L, Benayed R et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics 2012; 22: 577-589
13. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 2013; 9: e1003394
14. Umicevic Mirkov M, Cui J, Vermeulen SH, Stahl EA, Toonen EJ, Makkinje RR et al. Genome-wide association analysis of antiTNF drug response in patients with rheumatoid arthritis. Ann Rheum Dis 2012; 72: 1375-1381
15. Acosta-Colman I, Palau N, Tornero J, Fernandez-Nebro A, Blanco F, Gonzalez-lvaro I et al. GWAS replication study confirms the association of PDE3A-SLCO1C1 with antiTNF therapy response in rheumatoid arthritis. Pharmacogenomics 2013; 14: 727-734
16. Marquez A, Ferreiro-Iglesias A, Davila-Fajardo CL, Montes A, Pascual-Salcedo D, Perez-Pampin E et al. Lack of validation of genetic variants associated with antitumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-nalysis. Arthritis Res Ther 2014; 16: R66
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324
18. Julia A, Domenech E, Ricart E, Tortosa R, Garcia-Sanchez V, Gisbert JP et al. A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300. Gut 2012; 62: 1440-1445
19. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909
20. Alonso A, Marsal S, Tortosa R, Canela-Xandri O, Julia A. GStream: improving SNP and CNV coverage on genome-wide association studies. PLoS One 2013; 8: e68822
21. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575
22. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005 Suppl 5 23: S93-S99
23. Montes A, Perez-Pampin E, Narvaez J, Canete JD, Navarro-Sarabia F, Moreira V et al. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics 2014; 24: 238-245
24. Qiu W, Lazarus R Power Calculation for Testing If Disease is Associated with Marker in a Case-Control Study Using the GeneticsDesign Package: Cambridge 2010
25. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nat Methods 2012; 9: 179-181
26. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5: e1000529
27. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56-65
28. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010; 26: 2336-2337
29. Naar AM, Beaurang PA, Zhou S, Abraham S, Solomon W, Tjian R. Composite coactivator ARC mediates chromatin-directed transcriptional activation. Nature 1999; 398: 828-832
30. Kato Y, Habas R, Katsuyama Y, Naar AM, He X. A component of the ARC/Mediator complex required for TGF beta/Nodal signalling. Nature 2002; 418: 641-646
31. Jawad AF, McDonald-Mcginn DM, Zackai E, Sullivan KE. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr 2001; 139: 715-723
32. Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM. A census of human transcription factors: function, expression and evolution. Nat Rev Genet 2009; 10: 252-263
33. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-361
34. McInnes IB. Leukotrienes, mast cells, and T cells. Arthritis Res Ther 2003; 5: 288-289
35. Ortiz AM, Laffon A, Gonzalez-lvaro I. CD69 expression on lymphocytes and interleukin-15 levels in synovial fluids from different inflammatory arthropathies. Rheumatol Int 2002; 21: 182-188
36. Kang YM, Zhang X, Wagner UG, Yang H, Beckenbaugh RD, Kurtin PJ et al. CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis. J Exp Med 2002; 195: 1325-1336
37. Gemelli C, Montanari M, Tenedini E, Zanocco Marani T, Vignudelli T, Siena M et al. Virally mediated MafB transduction induces the monocyte commitment of human CD34+ hematopoietic stem/progenitor cells. Cell Death Differ 2006; 13: 1686-1696